Pharmaniaga Berhad

KLSE:PHARMA Stock Report

Market Cap: RM 475.6m

Pharmaniaga Berhad Future Growth

Future criteria checks 0/6

Pharmaniaga Berhad's revenue and earnings are forecast to decline at 0.2% and 40% per annum respectively while EPS is expected to decline by 39.6% per annum.

Key information

-40.0%

Earnings growth rate

-39.6%

EPS growth rate

Healthcare earnings growth3.1%
Revenue growth rate-0.2%
Future return on equityn/a
Analyst coverage

Low

Last updated29 Nov 2024

Recent future growth updates

Recent updates

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Jul 18
Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

May 09
Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Apr 19
Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Oct 03
Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Jul 19
Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Feb 18
Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Dec 10
Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Nov 24
Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Aug 27
We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Earnings and Revenue Growth Forecasts

KLSE:PHARMA - Analysts future estimates and past financials data (MYR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20253,5774935951
12/31/20243,5074629891
9/30/20243,62394-84-33N/A
6/30/20243,479-56-121-60N/A
3/31/20243,489-57-757N/A
12/31/20233,404-80-1447N/A
9/30/20233,477-689-76-15N/A
6/30/20233,487-654-2237N/A
3/31/20233,399-655-278-218N/A
12/31/20223,481-630-220-142N/A
9/30/20223,330100-186-105N/A
6/30/20224,568164145214N/A
3/31/20224,984177-2432N/A
12/31/20214,815172-109-64N/A
9/30/20214,73880-237N/A
6/30/20213,23032-394-356N/A
3/31/20212,69928-69-30N/A
12/31/20202,72527-58-26N/A
9/30/20202,806-145044N/A
6/30/20202,898-14648111N/A
3/31/20202,854-146-2146N/A
12/31/20192,821-149117190N/A
9/30/20192,70134108176N/A
6/30/20192,5724833106N/A
3/31/20192,55344100181N/A
12/31/20182,38542-154-82N/A
9/30/20182,40260-122-42N/A
6/30/20182,38848N/A-20N/A
3/31/20182,32452N/A-12N/A
12/31/20172,32454N/A239N/A
9/30/20172,29431N/A209N/A
6/30/20172,23441N/A231N/A
3/31/20172,24846N/A218N/A
12/31/20162,18946N/A35N/A
9/30/20162,28662N/A50N/A
6/30/20162,29669N/A54N/A
3/31/20162,27771N/A1N/A
12/31/20152,18984N/A7N/A
9/30/20152,136105N/A17N/A
6/30/20152,114100N/A52N/A
3/31/20152,12699N/A95N/A
12/31/20142,12394N/A213N/A
9/30/20142,06478N/A170N/A
6/30/20142,00267N/A140N/A
3/31/20141,91557N/A206N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PHARMA's earnings are forecast to decline over the next 3 years (-40% per year).

Earnings vs Market: PHARMA's earnings are forecast to decline over the next 3 years (-40% per year).

High Growth Earnings: PHARMA's earnings are forecast to decline over the next 3 years.

Revenue vs Market: PHARMA's revenue is expected to decline over the next 3 years (-0.2% per year).

High Growth Revenue: PHARMA's revenue is forecast to decline over the next 3 years (-0.2% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PHARMA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 05:11
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharmaniaga Berhad is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hsien Jin LamCGS International
Yee LowHong Leong Investment Bank Berhad
Ping-Khoon ChooKenanga Research